<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519036</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 443139-CS1</org_study_id>
    <nct_id>NCT02519036</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of
      multiple ascending doses of IONIS-HTTRx administered intrathecally to adult patients with
      early manifest Huntington's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2015</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (The number of participants with adverse events)</measure>
    <time_frame>Participants will be followed for the duration of the study; an expected 29 weeks</time_frame>
    <description>The number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability (The number of participants with adverse events)</measure>
    <time_frame>Participants will be followed for the duration of the study; an expected 29 weeks</time_frame>
    <description>The number of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF Pharmacokinetics (The observed CSF drug concentration)</measure>
    <time_frame>Day 1, Day 29, Day 57, Day 85, and Day 113 or Day 141</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak ISIS 443139 plasma concentration, Cmax (ug/mL)</measure>
    <time_frame>Day 1 and Day 85</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to peak ISIS 443139 plasma concentration, Tmax (hours)</measure>
    <time_frame>Day 1 and Day 85</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CSF huntingtin protein concentration (fM)</measure>
    <time_frame>Day 1, Day 29, Day 57, Day 85, and Day 113 or Day 141</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CSF neurofilament light chain (pg/mL)</measure>
    <time_frame>Day 1, Day 29, Day 57, Day 85, and Day 113 or Day 141</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular volume (mL)</measure>
    <time_frame>Screening, Day 113, and Day 197</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Huntington's disease cognitive assessment battery composite score (unitless)</measure>
    <time_frame>Screening, Day -1, Day 84, Day 141, and Day 197</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>IONIS HTTRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS HTTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, D and E.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS HTTRx</intervention_name>
    <arm_group_label>IONIS HTTRx</arm_group_label>
    <other_name>ISIS 443139</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosed with early manifest Huntington's disease

          -  Male or female, aged 25 to 65 years, inclusive, at the time of informed consent

          -  Able and willing to meet all study requirements, including travel to Study Center and
             participation in all procedures and measurements at study visits

          -  Have a trial partner who is reliable, competent and at least 18 years of age, is
             willing to accompany the patient to select trial visits and to be available to the
             Study Center by phone if needed

          -  Able to tolerate MRI scans, blood draws and lumbar punctures

          -  Reside within 4 hours travel of the Study Center

        Key Exclusion Criteria:

          -  Clinically significant medical condition, such as severe chorea, active suicidal
             ideation or any other conditions which would make the patient unsuitable for inclusion
             or could interfere with the patient participating in or completing the study

          -  Recent treatment with another investigational drug, biological agent, or device

          -  Prior treatment with an antisense oligonucleotide (including siRNA)

          -  Any history of gene therapy or cell transplantation or any other experimental brain
             surgery

          -  Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter

          -  History of post-lumbar-puncture headache of moderate or severe intensity and/or blood
             patch

          -  Malignancy within 5 years of Screening, except for basal or squamous cell carcinoma of
             the skin or carcinoma in situ of the cervix that has been successfully treated

          -  Hospitalization for any major medical or surgical procedure involving general
             anesthesia within 12 weeks of Screening or planned during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr-University of Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University Hospital</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester, St. Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ionispharma.com</url>
    <description>Ionis Pharmaceuticals, Inc. home page</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington's Disease</keyword>
  <keyword>HTTRx</keyword>
  <keyword>Early Manifest Huntington's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

